Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptive ...

The non-profit Drugs for Neglected Diseases initiative (DNDi) has joined forces with pharma group Serum Institute of India ...

The demise of the two programmes still leaves Roche with one Huntington's candidate, the gene therapy RG6662, which is in a ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

Alector has confirmed that an alliance with GSK to develop two drug candidates for dementia has been terminated in the wake ...

Vertex Pharma has made the largest acquisition in its history, agreeing to buy Crinetics Pharma for around $10 billion in a ...

Roche is also running the Krascendo 2 trial of divarasib plus MSD's PD-1 inhibitor Keytruda (pembrolizumab) in first-line ...

B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as ...

mResvia has been approved in the EU since 2024 to protect adults aged 60 years and older against lower respiratory tract ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...